Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

231.42
+0.39500.17%
Volume:2.30K
Turnover:529.29K
Market Cap:14.42B
PE:-52.39
High:231.42
Open:229.20
Low:229.20
Close:231.03
52wk High:248.60
52wk Low:124.06
Shares:62.32M
Float Shares:60.08M
Volume Ratio:0.08
T/O Rate:0.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4176
EPS(LYR):-4.4176
ROE:-818.43%
ROA:-6.86%
PB:-76.76
PE(LYR):-52.39

Loading ...

Ascendis Pharma weakness follows death reported in FAERS, says BofA

TIPRANKS
·
Oct 21, 2025

How Ascendis Pharma’s (ASND) TransCon CNP EMA Submission Has Shaped Its Rare Disease Investment Story

Simply Wall St.
·
Oct 19, 2025

Ascendis Pharma Initiated at Strong Buy by Raymond James

Dow Jones
·
Oct 17, 2025

Ascendis Pharma a/S : Raymond James Initiates Coverage With Strong Buy Rating; Target Price $271

THOMSON REUTERS
·
Oct 17, 2025

Raymond James Initiates Ascendis Pharma A/S at Strong Buy

MT Newswires Live
·
Oct 17, 2025

Ascendis Pharma initiated with a Strong Buy at Raymond James

TIPRANKS
·
Oct 17, 2025

Ascendis Pharma a/S : Wells Fargo Raises Target Price to $297 From $295

THOMSON REUTERS
·
Oct 15, 2025

Ascendis Pharma (ASND) Receives a Buy from Morgan Stanley

TIPRANKS
·
Oct 13, 2025

Ascendis Pharma Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Oct 13, 2025

Logista Pharma, Ascendis Pharma Sign Strategic Agreement For Hospital Distribution Of Yorvipath

Reuters
·
Oct 13, 2025

Ascendis Pharma (ASND) Is Up 6.9% After EMA Filing for TransCon CNP in Achondroplasia Treatment

Simply Wall St.
·
Oct 11, 2025

J.P. Morgan Sticks to Its Buy Rating for Ascendis Pharma (ASND)

TIPRANKS
·
Oct 10, 2025

Ascendis Submits Marketing Authorisation Application To The EMA

Reuters
·
Oct 09, 2025

Ascendis Pharma submits TransCon CNP for achondroplasia to EMA and FDA under review

Reuters
·
Oct 09, 2025

RBC Capital Keeps Their Buy Rating on Ascendis Pharma (ASND)

TIPRANKS
·
Oct 09, 2025

RBC Raises Price Target on Ascendis Pharma to $240 From $230, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Oct 08, 2025

Bank of America Securities Keeps Their Buy Rating on Ascendis Pharma (ASND)

TIPRANKS
·
Oct 08, 2025

Ascendis Pharma a/S : RBC Raises Target Price to $240 From $230

THOMSON REUTERS
·
Oct 08, 2025

Ascendis Pharma (ASND) Gets a Buy from Bank of America Securities

TIPRANKS
·
Oct 03, 2025

European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading

MT Newswires Live
·
Oct 02, 2025